FIGURE 1 from Identification of an Imidazopyridine-based Compound as an Oral Selective Estrogen Receptor Degrader for Breast Cancer Therapy
Year: 2023
Type: other
Abstract: Imidazopyridine structures for inhibition of prostate and breast cancer proliferation. A, Comparison of benzothiazole and imidazopyridine scaffolds. B, Chemical structures of the benzothiazole A4B17 and six imidazopyridines that potently inhibit clonal expansion of ER+ and AR+ breast and prostate cancer cells. C, Chemical structures showing the structure of different imidazopyridine derivatives. D, Crystal structures of X15695, X15696, and X19168.
Authors: Mengwu Pan, Valeria Solozobova, Nane C. Kuznik, Nicole Jung, Simone Gräßle, Victor Gourain, Yvonne M. Heneka, Christina A. Cramer von Clausbruch, Olaf Fuhr, Ravi S. N. Munuganti, Danilo Maddalo, Christine Blattner, Antje Neeb, Adam Sharp, Laura Cato, Carsten Weiss, Rinath M. Jeselsohn, Veronique Orian-Rousseau, Stefan Bräse, Andrew C. B. Cato
Language: English
Subfield: Genetics
Domain: Life Sciences
Open Access status: gold
OpenAlex ID: W4385303185